Efficacy and Safety of Ramucirumab With Docetaxel Versus Placebo With Docetaxel as Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer: A Subgroup Analysis According to Patient Age in the REVEL Trial
Year: 2017
Type: article
Source: Clinical Lung Cancer
Authors: Suresh S. Ramalingam, Maurice Pérol, Martin Reck, Ruben Dario Kowalyszyn, Oliver Gautschi, Martin Kimmich, Eun Kyung Cho, Grzegorz Czyzewicz, Alexandru Grigorescu, Nina Karaseva, Shaker Dakhil, Pablo Lee, Annamaria Zimmerman, Andreas Sashegyi, Ekaterine Alexandris, Gebra Cuyun Carter, Katherine B. Winfree, Edward B. Garon
Institutions: Emory University, Winship Cancer Institute, Centre Léon Bérard, German Center for Lung Research, LungenClinic Grosshansdorf, Luzerner Kantonsspital, Klinik Schillerhöhe, Gachon University Gil Medical Center, John Paul II Hospital, Institutul Oncologic Bucuresti, City Clinical Oncology Center, Cancer Center of Kansas, Eli Lilly (United States), University of California, Los Angeles
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
Funder: Eli Lilly and Company
OpenAlex ID: W2778540293